Status:

COMPLETED

A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participants Following Single Oral Dose Administration

Lead Sponsor:

AbbVie

Conditions:

Healthy Volunteer

Eligibility:

MALE

18-55 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to evaluate the mass balance and safety of \[14C\] ABBV-903 in healthy male volunteers following a single oral dose administration.

Eligibility Criteria

Inclusion

  • Body Mass Index (BMI) is \>= 18.0 to \<= 32.0 kg/m2 after rounding to the tenths decimal at Screening and upon initial confinement.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG).

Exclusion

  • History: of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), endocrine, metabolic, renal, hepatic, gastrointestinal, Gilbert's Syndrome, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness
  • History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to study drug administration.
  • Consider fathering a child or donating sperm during the study and for 94 days after study drug administration.
  • Has had significant exposure to radiation for professional or medical reasons (e.g., serial x-rays or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring), except dental x-rays, within 12 months prior to study drug administration.

Key Trial Info

Start Date :

August 18 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 13 2023

Estimated Enrollment :

7 Patients enrolled

Trial Details

Trial ID

NCT05995366

Start Date

August 18 2023

End Date

October 13 2023

Last Update

October 26 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Fortrea Clinical Research Unit Inc. /ID# 253962

Madison, Wisconsin, United States, 53704